Digest Network Come funziona
Network
/
Società
Pe
Non verificato

PeptiDream Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

8 comunicati stampa

Guarda tutti i comunicati
11/06/2026
Industria
Scienza
Medicina nucleare
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
Fonte
PeptiDream Inc.
Emittente
Business Wire
1.00
0
11/06/2026
Industria
Scienza
Medicina - Varie
Biotecnologia
Medicina nucleare
Farmaceutica
Vetrine/Shopping
Salute
Oncologia
PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Fonte
PeptiDream Inc.
Emittente
Business Wire
1.00
0
20/04/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Medicina nucleare
Farmaceutica
Biotecnologia
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
Fonte
PeptiDream Inc.
Emittente
Business Wire
1.00
0
18/12/2025
Industria
Biotecnologia
Salute
Scienza
Farmaceutica
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues
Fonte
PeptiDream Inc.
Emittente
Business Wire
1.00
0
17/12/2025
Industria
Biotecnologia
Salute
Scienza
Farmaceutica
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
Fonte
PeptiDream Inc.
Emittente
Business Wire
1.00
0
28/03/2025
Industria
Sanità
Medicina - Varie
Biologia
Biotecnologia
Medicina nucleare
Farmaceutica
Salute
Oncologia
National Cancer Center Japan and PeptiDream: New Radiopharmaceuticals for Renal Cell Carcinoma
Fonte
PeptiDream Inc.
Emittente
Business Wire
1.00
0
12/12/2024
Industria
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
PeptiDream Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer
Fonte
PeptiDream Inc.
Emittente
Business Wire
1.00
0
12/12/2024
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment
Fonte
PeptiDream Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0